Piper Sandler Maintains Overweight, $60 Price Target As Firm Believes There Is 'Massive Demand' for Palforzia, Notes 'AIMT has done an excellent job of preparing the market for this pioneering therapy.'

Benzinga · 02/03/2020 14:48